BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7548603)

  • 1. Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice.
    Brook I
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S376-7. PubMed ID: 7548603
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cefoxitin, cefotetan and the combination of ampicillin with sulbactam in the therapy of polymicrobial infection in mice.
    Brook I
    J Antimicrob Chemother; 1994 Nov; 34(5):791-6. PubMed ID: 7706175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.
    Brook I
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1531-5. PubMed ID: 8363386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of and therapy for polymicrobial infection in mice with cefoxitin, cefotetan, and cefmetazole.
    Brook I
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S425-6. PubMed ID: 8324161
    [No Abstract]   [Full Text] [Related]  

  • 6. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
    Brook I; Gillmore JD
    J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
    Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
    Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotics fail to prevent abscess formation secondary to bacteria trapped in fibrin clots.
    Hau T; Jacobs DE; Hawkins NL
    Arch Surg; 1986 Feb; 121(2):163-8. PubMed ID: 3511886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections.
    Falagas ME; Barefoot L; Griffith J; Ruthazar R; Snydman DR
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):913-21. PubMed ID: 9031873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of glucan and cefoxitin in prevention of murine abscess.
    Hull CC; Stellato TA; Rhodes RS; Galloway P; Hawkins NL
    Curr Surg; 1986; 43(5):416-8. PubMed ID: 3533446
    [No Abstract]   [Full Text] [Related]  

  • 11. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
    Gisby J; Beale AS
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
    Beale AS; Gisby J
    Infection; 1991; 19(2):101-5. PubMed ID: 2050417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative chemotherapeutic activity of temafloxacin, cefoxitin, clindamycin, imipenem and ampicillin/sulbactam against Bacteroides fragilis in a mouse subcutaneous abscess model.
    Alder J; Clement JJ
    J Antimicrob Chemother; 1993 Feb; 31(2):303-11. PubMed ID: 8463174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.
    Rice LB; Carias LL; Shlaes DM
    Antimicrob Agents Chemother; 1993 Mar; 37(3):610-2. PubMed ID: 8460928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ampicillin/sulbactam versus cefotetan for the prevention of infection following cesarean delivery in high-risk patients: a randomized double-blind trial.
    Bracero LA
    Gynecol Obstet Invest; 1997; 44(1):21-5. PubMed ID: 9251949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.
    Messick CR; Mamdani M; McNicholl IR; Danziger LH; Rodvold KA; Condon RE; Walker AP; Edmiston CE
    Pharmacotherapy; 1998; 18(1):175-83. PubMed ID: 9469691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
    Goldstein EJ; Citron DM; Cherubin CE
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1868-74. PubMed ID: 1952860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.